Anxo Pharmaceutical Co (ROCO:6677) Cash-to-Debt : 0.25 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Anxo Pharmaceutical Co's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.25.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Anxo Pharmaceutical Co couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Anxo Pharmaceutical Co's Cash-to-Debt or its related term are showing as below:

ROCO:6677' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 0.23 Max: 0.46
Current: 0.25

During the past 10 years, Anxo Pharmaceutical Co's highest Cash to Debt Ratio was 0.46. The lowest was 0.11. And the median was 0.23.

ROCO:6677's Cash-to-Debt is ranked worse than
72.14% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs ROCO:6677: 0.25

Anxo Pharmaceutical Co Cash-to-Debt Historical Data

The historical data trend for Anxo Pharmaceutical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Anxo Pharmaceutical Co Cash-to-Debt Chart

Anxo Pharmaceutical Co Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

0.18

0.21

0.25

0.26

0.30

Anxo Pharmaceutical Co Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial												0.23	0.26	0.26	0.30	0.25

Competitive Comparison of Anxo Pharmaceutical Co's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anxo Pharmaceutical Co's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's Cash-to-Debt falls into.

Anxo Pharmaceutical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Anxo Pharmaceutical Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	262.027	/	(326.398	+	561.651)
	=	0.30

Anxo Pharmaceutical Co's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	219.665	/	(350.177	+	528.127)
	=	0.25

Anxo Pharmaceutical Co (ROCO:6677) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Anxo Pharmaceutical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Anxo Pharmaceutical Co (ROCO:6677) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN

Website

http://www.anxo.com.tw

Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co (ROCO:6677) Headlines

No Headlines